{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:54:29Z","timestamp":1772582069021,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11894-025-01020-3","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T13:09:03Z","timestamp":1761138543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Kids on the Block: IL-23 Inhibitors in IBD Management"],"prefix":"10.1007","volume":"27","author":[{"given":"Jacob","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeevin","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dulaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"3","key":"1020_CR1","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.cgh.2024.06.049","volume":"23","author":"J Burisch","year":"2025","unstructured":"Burisch J, Claytor J, Hernandez I, Hou JK, Kaplan GG. The cost of inflammatory bowel disease care: how to make it sustainable. Clin Gastroenterol Hepatol. 2025;23(3):386\u201395.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"27","key":"1020_CR2","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383(27):2652\u201364.","journal-title":"N Engl J Med"},{"issue":"6","key":"1020_CR3","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1053\/j.gastro.2011.02.045","volume":"140","author":"D Burger","year":"2011","unstructured":"Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology. 2011;140(6):1827\u201337. e2.","journal-title":"Gastroenterology"},{"issue":"1","key":"1020_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","volume":"13","author":"S Ben-Horin","year":"2014","unstructured":"Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):24\u201330.","journal-title":"Autoimmun Rev"},{"key":"1020_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.765474","volume":"8","author":"Z Cai","year":"2021","unstructured":"Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Front Med. 2021;8:765474.","journal-title":"Front Med"},{"issue":"7","key":"1020_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","volume":"6","author":"D Alsoud","year":"2021","unstructured":"Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6(7):589\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"1020_CR7","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","volume":"160","author":"JD Feuerstein","year":"2021","unstructured":"Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing crohn\u2019s disease. Gastroenterology. 2021;160(7):2496\u2013508.","journal-title":"Gastroenterology"},{"issue":"7","key":"1020_CR8","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","volume":"167","author":"S Singh","year":"2024","unstructured":"Singh S, Loftus EV Jr., Limketkai BN, Haydek JP, Agrawal M, Scott FI, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024;167(7):1307\u201343.","journal-title":"Gastroenterology"},{"issue":"6","key":"1020_CR9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40259-020-00451-w","volume":"34","author":"A Almradi","year":"2020","unstructured":"Almradi A, Hanzel J, Sedano R, Parker CE, Feagan BG, Ma C, et al. Clinical trials of IL-12\/IL-23 inhibitors in inflammatory bowel disease. BioDrugs. 2020;34(6):713\u201321.","journal-title":"BioDrugs"},{"key":"1020_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637829","volume":"12","author":"C Schinocca","year":"2021","unstructured":"Schinocca C, Rizzo C, Fasano S, Grasso G, La Barbera L, Ciccia F, et al. Role of the IL-23\/IL-17 pathway in rheumatic diseases: an overview. Front Immunol. 2021;12:637829.","journal-title":"Front Immunol"},{"issue":"1","key":"1020_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2024.05.036","volume":"168","author":"AR Bourgonje","year":"2025","unstructured":"Bourgonje AR, Ungaro RC, Mehandru S, Colombel JF. Targeting the Interleukin 23 pathway in inflammatory bowel disease. Gastroenterology. 2025;168(1):29\u201352. e3.","journal-title":"Gastroenterology"},{"key":"1020_CR12","doi-asserted-by":"crossref","unstructured":"Biskup L, Semeradt J, Rogowska J, Chort W, Durko L, Malecka-Wojciesko E. New Interleukin-23 Antagonists\u2019 Use in Crohn\u2019s Disease. Pharmaceuticals (Basel). 2025;18(4).","DOI":"10.3390\/ph18040447"},{"key":"1020_CR13","doi-asserted-by":"crossref","unstructured":"Korta A, Kula J, Gomulka K. The role of IL-23 in the pathogenesis and therapy of inflammatory bowel disease. Int J Mol Sci. 2023;24(12).","DOI":"10.3390\/ijms241210172"},{"key":"1020_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/ITT.S282466","volume":"9","author":"A Jefremow","year":"2020","unstructured":"Jefremow A, Neurath MF. All are equal, some are more equal: targeting IL 12 and 23 in IBD - a clinical perspective. Immunotargets Ther. 2020;9:289\u201397.","journal-title":"Immunotargets Ther"},{"key":"1020_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.622934","volume":"12","author":"H Schmitt","year":"2021","unstructured":"Schmitt H, Neurath MF, Atreya R. Role of the IL23\/IL17 pathway in crohn\u2019s disease. Front Immunol. 2021;12:622934.","journal-title":"Front Immunol"},{"key":"1020_CR16","doi-asserted-by":"crossref","unstructured":"Colwill M, Baillie S, Clough J, Pollok R, Poullis A, Patel K et al. Role of Mirikizumab in the treatment of inflammatory bowel Disease-From bench to bedside. J Clin Med. 2025;14(3).","DOI":"10.3390\/jcm14031001"},{"issue":"12","key":"1020_CR17","first-page":"e51405","volume":"15","author":"CK Kerut","year":"2023","unstructured":"Kerut CK, Wagner MJ, Daniel CP, Fisher C, Henderson EJ, Burroughs CR, et al. Guselkumab, a novel monoclonal antibody inhibitor of the p19 subunit of IL-23, for psoriatic arthritis and plaque psoriasis: A review of its Mechanism, Use, and clinical effectiveness. Cureus. 2023;15(12):e51405.","journal-title":"Cureus"},{"issue":"1","key":"1020_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13706","volume":"17","author":"Y Pang","year":"2024","unstructured":"Pang Y, D\u2019Cunha R, Winzenborg I, Veldman G, Pivorunas V, Wallace K. Risankizumab. Mechanism of action, clinical and translational science. Clin Transl Sci. 2024;17(1):e13706.","journal-title":"Clin Transl Sci"},{"issue":"10340","key":"1020_CR19","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as induction therapy for crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015\u201330.","journal-title":"Lancet"},{"issue":"10340","key":"1020_CR20","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","volume":"399","author":"M Ferrante","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031\u201346.","journal-title":"Lancet"},{"key":"1020_CR21","doi-asserted-by":"crossref","unstructured":"Zinger A, Choi D, Choi N, Fear E, Fine Z, Cohen RD et al. Long-term Effectiveness and Safety of Risankizumab in Patients with Crohn\u2019s Disease. Clin Gastroenterol Hepatol. 2024.","DOI":"10.1016\/j.cgh.2024.09.027"},{"key":"1020_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf005","author":"R Panaccione","year":"2025","unstructured":"Panaccione R, Louis E, Colombel JF, D\u2019Haens G, Peyrin-Biroulet L, Dubinsky M, et al. Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf005.","journal-title":"J Crohns Colitis"},{"key":"1020_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1532852","volume":"16","author":"KL Sachen","year":"2025","unstructured":"Sachen KL, Hammaker D, Sarabia I, Stoveken B, Hartman J, Leppard KL, et al. Guselkumab binding to CD64(+) IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling. Front Immunol. 2025;16:1532852.","journal-title":"Front Immunol"},{"key":"1020_CR24","doi-asserted-by":"crossref","unstructured":"Kayal M. A practical guide to the use of Guselkumab for Moderate-Severe ulcerative colitis. Am J Gastroenterol. 2025.","DOI":"10.14309\/ajg.0000000000003446"},{"issue":"2","key":"1020_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","volume":"9","author":"S Danese","year":"2024","unstructured":"Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, et al. Efficacy and safety of 48 weeks of Guselkumab for patients with Crohn\u2019s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024;9(2):133\u201346.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"1020_CR26","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1007\/s12325-025-03183-x","volume":"42","author":"T Disher","year":"2025","unstructured":"Disher T, Naessens D, Sanon M, Bonner A, Ellis J, Bartlett M, et al. One-year efficacy of Guselkumab versus advanced therapies for the treatment of moderately to severely active Crohn\u2019s disease: a network meta-analysis. Adv Ther. 2025;42(6):2708\u201327.","journal-title":"Adv Ther"},{"key":"1020_CR27","doi-asserted-by":"crossref","unstructured":"Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q et al. Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn\u2019s Disease: Results From the Phase 3 GRAVITI Study. Gastroenterology. 2025.","DOI":"10.1016\/S0016-5085(25)02905-1"},{"issue":"6","key":"1020_CR28","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","volume":"165","author":"L Peyrin-Biroulet","year":"2023","unstructured":"Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, et al. Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study. Gastroenterology. 2023;165(6):1443\u201357.","journal-title":"Gastroenterology"},{"issue":"6","key":"1020_CR29","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(23)04757-1","volume":"164","author":"JR Allegretti","year":"2023","unstructured":"Allegretti JR, Peyrin-Biroulet L, Feagan BG, et al. The efficacy and safety of Guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR induction study. Gastroenterology. 2023;164(6):S\u20131572.","journal-title":"Gastroenterology"},{"issue":"1","key":"1020_CR30","doi-asserted-by":"publisher","first-page":"i19","DOI":"10.1093\/ecco-jcc\/jjae190.0010","volume":"19","author":"L Peyrin-Biroulet","year":"2025","unstructured":"Peyrin-Biroulet L, Danese JRAS, Germinaro M, Baker T, Alvarez Y, J\u00f6rgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Long M. Efficacy and safety of subcutaneous Guselkumab induction therapy in patients with ulcerative colitis: results through week 12 from the phase 3 ASTRO study. J Crohn\u2019s Colitis. 2025;19(1):i19\u201320.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"11","key":"1020_CR31","first-page":"1045","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ, Mirikizumab. First Approval Drugs. 2023;83(11):1045\u201352.","journal-title":"First Approval Drugs"},{"issue":"2","key":"1020_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1124\/jpet.122.001512","volume":"387","author":"B Steere","year":"2023","unstructured":"Steere B, Beidler C, Martin A, Bright S, Kikly K, Benschop RJ. Generation and characterization of Mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23. J Pharmacol Exp Ther. 2023;387(2):180\u20137.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1020_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","volume":"162","author":"BE Sands","year":"2022","unstructured":"Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, et al. Efficacy and safety of Mirikizumab in a randomized phase 2 study of patients with crohn\u2019s disease. Gastroenterology. 2022;162(2):495\u2013508.","journal-title":"Gastroenterology"},{"issue":"26","key":"1020_CR34","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444\u201355.","journal-title":"N Engl J Med"},{"issue":"12","key":"1020_CR35","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/ibd\/izae024","volume":"30","author":"BE Sands","year":"2024","unstructured":"Sands BE, D\u2019Haens G, Clemow DB, Irving PM, Johns JT, Hunter Gibble T, et al. Two-year efficacy and safety of Mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study. Inflamm Bowel Dis. 2024;30(12):2245\u201358.","journal-title":"Inflamm Bowel Dis"},{"key":"1020_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1490667","volume":"16","author":"SS Wang","year":"2025","unstructured":"Wang SS, Wan H, Xiao Q. Efficacy and safety of IL-23 p19 inhibitors in the treatment for inflammatory bowel disease: a systematic review and meta-analysis. Front Pharmacol. 2025;16:1490667.","journal-title":"Front Pharmacol"},{"issue":"10463","key":"1020_CR37","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/S0140-6736(24)01750-1","volume":"404","author":"VF Jairath","year":"2024","unstructured":"Jairath VF, Cho MLA. IL-23 inhibition for chronic inflammatory disease. Lancet. 2024;404(10463):1679\u201392.","journal-title":"Lancet"},{"issue":"1","key":"1020_CR38","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"AP Blauvelt","year":"2017","unstructured":"Blauvelt AP, Griffiths KA. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator\u2013controlled voyage 1 trial. J Am Acad Dermatol. 2017;76(1):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1020_CR39","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"KA Reich","year":"2017","unstructured":"Reich KA, Foley AW. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator\u2013controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1020_CR40","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","volume":"391","author":"LC Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet LC, Colombel JC. Risankizumab versus ustekinumab for moderate-to-severe crohn\u2019s disease. N Engl J Med. 2024;391(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"10470","key":"1020_CR41","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","volume":"404","author":"M Ferrante","year":"2024","unstructured":"Ferrante M, D\u2019Haens G, Jairath V, Danese S, Chen M, Ghosh S, et al. Efficacy and safety of Mirikizumab in patients with moderately-to-severely active crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet. 2024;404(10470):2423\u201336.","journal-title":"Lancet"},{"issue":"8","key":"1020_CR42","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/MCG.0000000000001583","volume":"55","author":"ML Haider","year":"2021","unstructured":"Haider ML. Dual targeted therapy for the management of inflammatory bowel disease. J Clin Gastroenterol. 2021;55(8):661\u20136.","journal-title":"J Clin Gastroenterol"},{"key":"1020_CR43","doi-asserted-by":"crossref","unstructured":"Alayo QF, Altayar M. O.; Systematic review with Meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease. Crohn\u2019s Colitis 360. 2022;4(1).","DOI":"10.1093\/crocol\/otac002"},{"issue":"4","key":"1020_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11041076","volume":"11","author":"EBC Mas","year":"2022","unstructured":"Mas EBC. Selecting the best combined biological therapy for refractory inflammatory bowel disease patients. J Clin Med. 2022;11(4):1076.","journal-title":"J Clin Med"},{"issue":"2","key":"1020_CR45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/ecco-jcc\/jjaa149","volume":"15","author":"GO Privitera","year":"2020","unstructured":"Privitera GO, Pugliese S. et. al. Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease. J Crohns Colitis. 2020;15(2):335\u20139.","journal-title":"J Crohns Colitis"},{"key":"1020_CR46","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","volume":"8","author":"BGS Feagan","year":"2023","unstructured":"Feagan BGS, Sandbor BE. et.al. Guselkumab plus golimumab combination therapy versus Guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8:307\u201320.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1020_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38541-2","volume":"14","author":"CS Lay","year":"2023","unstructured":"Lay CS, Isidro-Llobet A, Kilpatrick LE, Craggs PD, Hill SJ. Characterisation of IL-23 receptor antagonists and disease relevant mutants using fluorescent probes. Nat Commun. 2023;14(1):2882.","journal-title":"Nat Commun"},{"issue":"4","key":"1020_CR48","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/ecco-jcc\/jjad173","volume":"18","author":"DC Hindmarch","year":"2024","unstructured":"Hindmarch DC, Malashanka S, Shows DM, Clarke AS, Lord JD. Janus kinase inhibitors differentially inhibit specific cytokine signals in the mesenteric lymph node cells of inflammatory bowel disease patients. J Crohns Colitis. 2024;18(4):628\u201337.","journal-title":"J Crohns Colitis"},{"key":"1020_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf080","author":"G D\u2019Haens","year":"2025","unstructured":"D\u2019Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, et al. Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn\u2019s disease and ulcerative colitis. J Crohns Colitis. 2025. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf080.","journal-title":"J Crohns Colitis"},{"issue":"17","key":"1020_CR50","first-page":"1671","volume":"82","author":"SM Hoy","year":"2022","unstructured":"Hoy SM, Deucravacitinib. First Approval Drugs. 2022;82(17):1671\u20139.","journal-title":"First Approval Drugs"},{"issue":"10","key":"1020_CR51","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","volume":"21","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, Altintas E, Peeva E, et al. Oral Ritlecitinib and brepocitinib for Moderate-to-Severe ulcerative colitis: results from a Randomized, phase 2b study. Clin Gastroenterol Hepatol. 2023;21(10):2616\u201328. e7.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1020_CR52","doi-asserted-by":"publisher","first-page":"19422","DOI":"10.1038\/s41598-021-97236-0","volume":"11","author":"KJ Roberts","year":"2021","unstructured":"Roberts KJ, Cubitt MF, Carlton TM, Rodrigues-Duarte L, Maggiore L, Chai R, et al. Preclinical development of a bispecific TNFalpha\/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. Sci Rep. 2021;11(1):19422.","journal-title":"Sci Rep"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-01020-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-025-01020-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-01020-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:02:31Z","timestamp":1772578951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-025-01020-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1007\/s11894-025-01020-3","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.P. receives consulting fees from AbbVie and speaker fees from J&J, Eli Lilly, and AbbVie. D.D. is a speaker for Eli Lilly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}